In the new 2016 WHO classification, each diagnostic category of diffuse glioma is defined by combining genotype and phenotype, which indicates the importance of molecular biomarkers, such as isocitrate dehydrogenase (IDH), mutational status in glioma has been recognized. This evidence concerns the gene IDH1 and central nervous system cancer.